Key result
Neither cisapride nor metoclopramide significantly improved oesophageal transit, gastric emptying, whole-gut transit, or symptoms compared to placebo in diabetic autonomic neuropathy.
Why the study?
Do oral cisapride and metoclopramide improve gastrointestinal transit and symptoms in diabetic patients with autonomic neuropathy?
RCT (n=19)
Double-blind
Do oral cisapride and metoclopramide improve gastrointestinal transit and symptoms in diabetic patients with autonomic neuropathy?
Oral cisapride and metoclopramide do not significantly improve objective gastrointestinal transit abnormalities or symptoms in patients with diabetic autonomic neuropathy.
Answers are grounded in this paper and cite their sources.
Does not support cisapride or metoclopramide for GI symptoms in diabetic autonomic neuropathy; challenges prior assumptions of prokinetic efficacy.
Nineteen diabetic patients with autonomic neuropathy were enrolled in a double-blind crossover study of cisapride, metoclopramide and placebo. Symptoms were evaluated from diary cards and from assessments undertaken at the end of each eight week treatment period. Measurements of oesophageal transit, gastric emptying and whole gut transit were made before treatment began and at the end of each treatment period. Three patients dropped out early in the study, and the results from 16 patients were analysed. The severity of autonomic neuropathy, judged from cardiovascular reflex tests, correlated with delayed oesophageal transit and prolonged gastric emptying, but abnormal oesophageal transit and gastric emptying were often unrelated to the presence of upper gastrointestinal symptoms. Neither cisapride nor metoclopramide had a statistically significant effect on oesophageal transit, gastric emptying or whole-gut transit, nor was any significant effect on symptoms identified, although a trend towards reduced nausea and vomiting with metoclopramide and reduced epigastric fullness and diarrhoea with cisapride was suggested. Upper gastrointestinal symptoms correlate poorly with objective abnormalities of gastrointestinal motor function in diabetes. In consequence, the symptomatic benefit to be expected from correction of these motor abnormalities remains uncertain.
No takes yet. Share an insight, caveat, or question.
Caestecker et al. (1989) conducted an RCT in Diabetic autonomic neuropathy (n=19). Cisapride and metoclopramide vs. Placebo was evaluated on Oesophageal transit, gastric emptying, whole gut transit, and symptoms. Neither cisapride nor metoclopramide significantly improved oesophageal transit, gastric emptying, whole-gut transit, or symptoms compared to placebo in diabetic autonomic neuropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: